Staas
David Staas, Menlo Park, CA US
Patent application number | Description | Published |
---|---|---|
20140012806 | LOCATION GRAPH BASED DERIVATION OF ATTRIBUTES - Location graph-based derivation of user attributes is disclosed. In various embodiments, location data associated with a user, such as a current and/or past location at which the user has been, is received. A user attribute data associated with the location data is determined and used to update a user profile associated with the user. | 01-09-2014 |
20150052132 | LOCATION GRAPH BASED DERIVATION OF ATTRIBUTES - Location graph-based derivation of user attributes is disclosed. In various embodiments, location data associated with a user, such as a current and/or past location at which the user has been, is received. A user attribute data associated with the location data is determined and used to update a user profile associated with the user. | 02-19-2015 |
David Edward Staas, Vancouver, WA US
Patent application number | Description | Published |
---|---|---|
20130290656 | Concurrent Request Scheduling | 10-31-2013 |
David Edward Staas, Camas, WA US
Patent application number | Description | Published |
---|---|---|
20100290078 | Parallelization In Printing - Disclosed are various embodiments of various systems that facilitate the printing of documents. In one representative example, one arrangement includes a plurality of raster image processors, a plurality of frame brokers, and a first digital switch facilitating communication between the raster image processors and frame brokers. The arrangement also includes a plurality of printers and a second digital switch facilitating communication between the frame brokers and the printers. A central control system orchestrates a progression of frames of a plurality of documents through the raster image processors and the frame brokers to the printers. | 11-18-2010 |
Deron J. Staas, Rockford, IL US
Patent application number | Description | Published |
---|---|---|
20100253294 | STARTER VOLTAGE REDUCING SYNCHRONOUS MACHINE - An electric power generation system has a synchronous machine, a starter excitation source and an exciter field driver. The starter excitation source is connected to the synchronous machine via multiple phase connections, and the exciter field driver is connected to the synchronous machine via a portion of the same phase connections. At least one of the phase connections is connected to each other phase connection via a transient voltage suppressor. | 10-07-2010 |
Donnette Staas, Harleysville, PA US
Patent application number | Description | Published |
---|---|---|
20100056516 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS - 1-Hydroxy naphthyridine compounds (e.g., 1-hydroxy naphthyridin-2(1H)-one compounds of Formula I are inhibitors of HIV integrase and/or HIV RNase H and inhibitors of HIV replication: (I) wherein X and R1-R6 are as defined herein. The compounds are useful in the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other anti-HIV agents such as HIV antivirals, immunomodulators, antibiotics and vaccines. | 03-04-2010 |
Donnette D. Staas, Harleysville, PA US
Patent application number | Description | Published |
---|---|---|
20080287394 | Hiv Integrase Inhibitors - Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R | 11-20-2008 |
20110021516 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS - The present invention is directed to compounds of the formula (I): (wherein variables A | 01-27-2011 |
20110224201 | CGRP RECEPTOR ANTAGONISTS - Compounds of Formula (I), (wherein variables A | 09-15-2011 |
20150031716 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS - The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 01-29-2015 |
Donnette D. Staas, West Point, PA US
Patent application number | Description | Published |
---|---|---|
20110245240 | CGRP RECEPTOR ANTAGONISTS - Compounds of Formula (I): (wherein variables A | 10-06-2011 |
Donnette D. Staas, Holland, PA US
Patent application number | Description | Published |
---|---|---|
20120122899 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS - The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 05-17-2012 |
20120122900 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS - The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 05-17-2012 |
20130231358 | PIPERIDINONE CARBOXAMIDE INDANE CGRP RECEPTOR ANTAGONISTS - The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 09-05-2013 |
Ernst Staas, Limburg DE
Patent application number | Description | Published |
---|---|---|
20100200380 | Switch Assembly for a Power Tool - A switch assembly for a power tool comprises a switch member and a fixing part. The switch member comprises a finger grip part, a retaining part for retaining the switch member on a power tool, and an opening extending at least partially through the switch member, the retaining part arranged to project laterally with respect to an axis of the opening. The fixing part is arranged to be located in the opening. The switch assembly is arranged such that when the fixing part is at a first location in the opening, the retaining part adopts a retention configuration in which it projects laterally to a predetermined extent. When the fixing part is removed or at a second location in the opening, the retaining part adopts an insertion configuration in which it does not project laterally or projects less than the predetermined extent. | 08-12-2010 |
20150014009 | Hammer Drill - A hammer drill comprises a motor including an output shaft, a shaft assembly rotationally engaged therewith, a hollow spindle, and a hammer mechanism comprising a piston arranged for reciprocating motion within the spindle. The shaft assembly comprises a first part carrying a first gear engaged with a gear on the spindle to cause spindle rotation, a second part carrying a crank member to cause piston reciprocation, and a connecting part configured to rotationally interconnect, or disconnect, the first and second parts. In a first position of the connecting part only one of the first and second parts is rotationally engaged with the output shaft to enable rotation of only one of the first gear and the crank member respectively, while in a second position both the first and second parts are rotationally engaged with the output shaft to enable rotation of both the first gear and the crank member. | 01-15-2015 |
20150014011 | Power Tool - A power tool comprises a housing having at least two housing parts and at least one recess, a portion of the recess provided by each housing part, and a bearing located in the recess. The power tool includes a seal comprising an elongate seal member located between the housing parts to seal at least a portion of the housing. The seal includes at least one polymeric extension part extending from the elongate seal member and in contact with an external part of the bearing without extending around the bearing. The polymeric extension part of the seal prevents the external part of the bearing from rotating with respect to the housing during use of the power tool. | 01-15-2015 |
Jay K. Staas, Pelham, AL US
Patent application number | Description | Published |
---|---|---|
20080305115 | Reduced-mass, long-acting dosage forms - Methods and compositions are disclosed whereby free antibody or nucleic acid co-administered with a long-acting formulation, such as a microparticle or implant, containing the antibody or nucleic acid to achieve a long duration of antibody or nucleic acid release. One result is that less of the long-acting formulation excipient or polymer is needed allowing for small-volume administrations as required, for example, for ocular, intra-dermal, orthopedic, brain and spinal delivery. In one aspect, the free antibody or nucleic acid alone has efficacy for an extended period, during which time, very little or no long-acting formulation antibody or nucleic acid is released. In one aspect, after the free antibody or nucleic acid has diminished activity, is gone, or no longer has activity, the long-acting formulation antibody or nucleic acid begins to release for a desired preprogrammed duration to provide long-acting durations. Less formulation mass is needed because the entire antibody or nucleic acid is not encapsulated or implanted with encapsulation or implant excipient or polymer. In addition, more antibody or nucleic acid can be administered to afford longer-acting formulations. | 12-11-2008 |
Jay K. Staas, Maylene, AL US
Patent application number | Description | Published |
---|---|---|
20080305152 | Methods of Inducing Melanogenesis in a Subject - Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors. | 12-11-2008 |
Jay K. Staas, Madison, AL US
Patent application number | Description | Published |
---|---|---|
20140037707 | Methods for Manufacturing Delivery Systems and Systems Thereof - Described herein are methods for reducing and achieving the desired release of an agent from a delivery system. The desired release kinetics are achieved by exposing the surface of the delivery system with a fluid for a desired period of time. | 02-06-2014 |